Early tests suggest that coronavirus antibody therapy developed by Regeneron Pharmaceuticals is losing its effectiveness against the Omicron variant, but the full impact will be known in the coming weeks after further studies, the president told the Wall Street Journal. Head of the Scientific Team of the company, George Yancopoulos.
It is recalled that the Omicron variant was identified in South Africa and was described as a “concern variant” by the World Health Organization on Friday, which led many countries to impose restrictions on travel to and from South Africa.
Meanwhile, a separate study on antibody therapy developed by Eli Lilly & Co. shows that it is also less effective than Omicron.
The researchers say that some antibody therapies may be vulnerable to Omicron because they contain mutations in the spike protein that Regeneron and Lilly therapies target.
Yancopoulos stressed that the company is already working on alternative antibodies that will fight Omicron.
.
Source From: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.